Cargando…

Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care

AIMS: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. METHODS AND RESULTS: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Okazaki, Hirotake, Shirakabe, Akihiro, Matsushita, Masato, Shibata, Yusaku, Sawatani, Tomofumi, Uchiyama, Saori, Tani, Kennichi, Murase, Takayo, Nakamura, Takashi, Takayasu, Tsutomu, Asano, Miwako, Kobayashi, Nobuaki, Hata, Noritake, Asai, Kuniya, Shimizu, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437423/
https://www.ncbi.nlm.nih.gov/pubmed/30620450
http://dx.doi.org/10.1002/ehf2.12390
_version_ 1783406945284128768
author Okazaki, Hirotake
Shirakabe, Akihiro
Matsushita, Masato
Shibata, Yusaku
Sawatani, Tomofumi
Uchiyama, Saori
Tani, Kennichi
Murase, Takayo
Nakamura, Takashi
Takayasu, Tsutomu
Asano, Miwako
Kobayashi, Nobuaki
Hata, Noritake
Asai, Kuniya
Shimizu, Wataru
author_facet Okazaki, Hirotake
Shirakabe, Akihiro
Matsushita, Masato
Shibata, Yusaku
Sawatani, Tomofumi
Uchiyama, Saori
Tani, Kennichi
Murase, Takayo
Nakamura, Takashi
Takayasu, Tsutomu
Asano, Miwako
Kobayashi, Nobuaki
Hata, Noritake
Asai, Kuniya
Shimizu, Wataru
author_sort Okazaki, Hirotake
collection PubMed
description AIMS: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. METHODS AND RESULTS: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood samples were collected within 15 min of admission from AHF patients (AHF group) and control patients who visited a daily cardiovascular outpatient clinic (control group). Plasma XOR activity was compared between the two groups, and factors independently associated with extremely elevated XOR activity were identified using a multivariate logistic regression model. Plasma XOR activity in the AHF group (median, 104.0 pmol/h/mL; range, 25.9–423.5 pmol/h/mL) was significantly higher than that in the control group (median, 45.2 pmol/h/mL; range, 19.3–98.8 pmol/h/mL). The multivariate logistic regression model showed that serum uric acid (per 1.0 mg/dL increase, odds ratio: 1.280; 95% confidence interval: 1.066–1.536; P = 0.008) and lactate levels (per 1.0 mmol/L increase, odds ratio: 1.239; 95% confidence interval: 1.040–1.475; P = 0.016) were independently associated with high plasma XOR activity (>300 pg/h/mL) during the acute phase of AHF. CONCLUSIONS: Plasma XOR activity was extremely high in patients with severely decompensated AHF. This would be associated with a high lactate value and would eventually lead to hyperuricaemia in patients with AHF.
format Online
Article
Text
id pubmed-6437423
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64374232019-04-10 Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care Okazaki, Hirotake Shirakabe, Akihiro Matsushita, Masato Shibata, Yusaku Sawatani, Tomofumi Uchiyama, Saori Tani, Kennichi Murase, Takayo Nakamura, Takashi Takayasu, Tsutomu Asano, Miwako Kobayashi, Nobuaki Hata, Noritake Asai, Kuniya Shimizu, Wataru ESC Heart Fail Original Research Articles AIMS: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. METHODS AND RESULTS: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood samples were collected within 15 min of admission from AHF patients (AHF group) and control patients who visited a daily cardiovascular outpatient clinic (control group). Plasma XOR activity was compared between the two groups, and factors independently associated with extremely elevated XOR activity were identified using a multivariate logistic regression model. Plasma XOR activity in the AHF group (median, 104.0 pmol/h/mL; range, 25.9–423.5 pmol/h/mL) was significantly higher than that in the control group (median, 45.2 pmol/h/mL; range, 19.3–98.8 pmol/h/mL). The multivariate logistic regression model showed that serum uric acid (per 1.0 mg/dL increase, odds ratio: 1.280; 95% confidence interval: 1.066–1.536; P = 0.008) and lactate levels (per 1.0 mmol/L increase, odds ratio: 1.239; 95% confidence interval: 1.040–1.475; P = 0.016) were independently associated with high plasma XOR activity (>300 pg/h/mL) during the acute phase of AHF. CONCLUSIONS: Plasma XOR activity was extremely high in patients with severely decompensated AHF. This would be associated with a high lactate value and would eventually lead to hyperuricaemia in patients with AHF. John Wiley and Sons Inc. 2019-01-08 /pmc/articles/PMC6437423/ /pubmed/30620450 http://dx.doi.org/10.1002/ehf2.12390 Text en © 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Okazaki, Hirotake
Shirakabe, Akihiro
Matsushita, Masato
Shibata, Yusaku
Sawatani, Tomofumi
Uchiyama, Saori
Tani, Kennichi
Murase, Takayo
Nakamura, Takashi
Takayasu, Tsutomu
Asano, Miwako
Kobayashi, Nobuaki
Hata, Noritake
Asai, Kuniya
Shimizu, Wataru
Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
title Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
title_full Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
title_fullStr Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
title_full_unstemmed Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
title_short Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
title_sort plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437423/
https://www.ncbi.nlm.nih.gov/pubmed/30620450
http://dx.doi.org/10.1002/ehf2.12390
work_keys_str_mv AT okazakihirotake plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT shirakabeakihiro plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT matsushitamasato plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT shibatayusaku plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT sawatanitomofumi plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT uchiyamasaori plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT tanikennichi plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT murasetakayo plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT nakamuratakashi plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT takayasutsutomu plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT asanomiwako plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT kobayashinobuaki plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT hatanoritake plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT asaikuniya plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare
AT shimizuwataru plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare